Study guide
6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State
Key Takeaways Explain This Topic AI
Diabetic ketoacidosis (DKA) is diagnosed by the biochemical triad of hyperglycaemia (blood glucose > 11.0 mmol/L or known diabetes), ketonaemia (blood beta-hydroxybutyrate ≥ 3.0 mmol/L or urine ketones ≥ ++), and metabolic acidosis (venous pH < 7.30 or bicarbonate < 15.0 mmol/L); euglycaemic DKA can occur in patients taking SGLT2 inhibitors.
The cornerstone of DKA management (JBDS protocol) is rapid crystalloid fluid resuscitation with 0.9% sodium chloride combined with a Fixed-Rate Intravenous Insulin Infusion (FRIII at 0.1 units/kg/h) based on actual body weight, while continuing long-acting subcutaneous basal insulin.
Potassium management in DKA requires strict adherence: omit potassium from the initial 1-litre bag; add 40 mmol KCl per litre bag if serum K+ is 3.5–5.5 mmol/L, omit KCl if K+ > 5.5 mmol/L, and seek senior review because additional potassium is needed if K+ < 3.5 mmol/L; never stop the insulin infusion.
Hyperosmolar Hyperglycaemic State (HHS) is characterized by severe hyperglycaemia (> 30 mmol/L), profound hyperosmolality (> 320 mOsm/kg), and severe dehydration without significant ketoacidosis; initial therapy is 0.9% NaCl fluid resuscitation alone (insulin 0.05 units/kg/h is added only if glucose ceases to fall), alongside mandatory prophylactic LMWH due to high thromboembolic risk.
Last updated: October 2026
Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State
Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycaemic State (HHS) represent life-threatening acute metabolic emergencies. Rapid diagnosis, prompt crystalloid rehydration, structured insulin administration, and vigilant electrolyte monitoring form the foundation of management according to Joint British Diabetes Societies (JBDS) and NICE guideline NG17/NG28.
Diabetic Ketoacidosis (DKA)
DKA results from an absolute or severe relative deficiency of circulating insulin combined with an excess of counter-regulatory hormones (glucagon, adrenaline, cortisol, and growth hormone). This hormonal imbalance accelerates lipolysis in peripheral adipocytes, releasing free fatty acids that undergo hepatic mitochondrial beta-oxidation into ketone bodies ( acetoacetate and beta-hydroxybutyrate ). Concurrently, hepatic gluconeogenesis and glycogenolysis cause severe hyperglycaemia, inducing osmotic diuresis, profound electrolyte depletion, and hypovolaemia.
The Diagnostic Triad
Diagnosis requires the simultaneous presence of three biochemical components:
Hyperglycaemia: Blood glucose > 11.0 mmol/L (or known diabetes mellitus).
Ketonaemia: Capillary blood beta-hydroxybutyrate ≥ 3.0 mmol/L (or urine ketones ≥ ++ on dipstick).
Acidosis: Venous blood gas (VBG) showing pH < 7.30 or serum bicarbonate < 15.0 mmol/L.
Important
Euglycaemic DKA: Patients taking SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) can develop severe ketoacidosis with normal or only mildly elevated blood glucose levels (< 11.0 mmol/L). Glucosuria maintains near-normal glycaemia despite profound relative insulin deficiency and ongoing ketogenesis. When a patient on an SGLT2 inhibitor presents with nausea, vomiting, abdominal pain, or tachypnoea, blood ketones and venous blood gases must be checked immediately regardless of capillary glucose.
JBDS DKA Resuscitation Protocol
Management of DKA requires three concurrent interventions delivered in a high-dependency setting: intravenous crystalloid fluids, fixed-rate intravenous insulin, and potassium replacement.
1. Fluid Resuscitation
The average adult fluid deficit in DKA is 100 mL/kg (5–8 litres). The standard replacement fluid is 0.9% sodium chloride :
1st litre: Infuse over 1 hour (do NOT add potassium to this first bag).
2nd litre: Infuse over 2 hours (with KCl added based on serum potassium).
3rd litre: Infuse over 2 hours (with KCl).
4th litre: Infuse over 4 hours (with KCl).
5th litre: Infuse over 4 hours (with KCl).
6th litre: Infuse over 6 hours (with KCl).
Caution: In elderly patients, heart failure, or renal impairment, fluid rates must be modified to prevent fluid overload and pulmonary oedema.
Introducing 10% Dextrose: When capillary blood glucose drops below 14.0 mmol/L , immediately commence 10% glucose at 125 mL/hour alongside the 0.9% sodium chloride infusion, and (JBDS 2023) consider reducing the fixed-rate insulin infusion from 0.1 to 0.05 units/kg/hour to lower the risk of hypoglycaemia. Never stop the insulin infusion : insulin must continue to suppress ketogenesis and clear the acidosis, with glucose preventing hypoglycaemia.
2. Fixed-Rate Intravenous Insulin Infusion (FRIII)
Administer soluble human insulin (Actrapid or Humulin S) at a fixed rate of 0.1 units/kg/hour calculated from the patient's actual weight (prepared by adding 50 units of soluble insulin to 50 mL 0.9% NaCl, delivered via a syringe pump at 0.1 mL/kg/h).
Basal Subcutaneous Insulin Rule: DO NOT stop the patient's usual long-acting basal insulin (e.g., Lantus, Levemir, Tresiba, Toujeo). Basal insulin must be continued at its normal dose and timing to prevent rebound hyperglycaemia and ketoacidosis when the intravenous insulin infusion is eventually discontinued.
3. Potassium Replacement Protocol
Insulin drives potassium into cells, and rehydration dilutes serum potassium while increasing urinary kaliuresis. Without replacement, hypokalaemia develops rapidly, risking lethal ventricular arrhythmias.
Measured Serum Potassium (mmol/L) Potassium Chloride (KCl) Replacement per 1-Litre Bag of 0.9% NaCl
> 5.5 mmol/L Nil KCl added. Check serum potassium hourly.
3.5 – 5.5 mmol/L Add 40 mmol KCl per 1-litre bag.
< 3.5 mmol/L Seek immediate senior review: additional potassium is required (JBDS 2023). Concentrated potassium may need a high-dependency setting and central access; monitor potassium and ECG closely.
Monitoring Targets & DKA Resolution
Hourly monitoring: Capillary blood glucose and blood beta-hydroxybutyrate.
Venous blood gas (VBG) & electrolytes: Check at 2, 4, 8, 12, and 24 hours.
Physiological targets:
Reduction of capillary blood ketones by ≥ 0.5 mmol/L/hour .
Rise in venous bicarbonate by ≥ 3.0 mmol/L/hour .
Fall in capillary blood glucose by ≥ 3.0 mmol/L/hour .
Maintain serum potassium strictly between 4.0 and 5.0 mmol/L.
If targets are not met: Check line patency, verify infusion rates, and increase the FRIII rate by 1.0 unit/hour increments.
Criteria for DKA Resolution
DKA is resolved when all of the following criteria are met:
Capillary blood beta-hydroxybutyrate < 0.6 mmol/L , AND
Venous blood gas pH > 7.3 .
JBDS 2023 advises not using bicarbonate as the marker of resolution, because 0.9% saline causes a hyperchloraemic acidosis that keeps bicarbonate low after the ketoacidosis has cleared.
Before converting to subcutaneous insulin, the patient should also be eating and drinking.
Note
Transition to Subcutaneous Insulin: Convert back to subcutaneous insulin only when the patient is ready to eat. Administer the patient's subcutaneous rapid-acting prandial insulin and basal insulin with a meal, and continue the FRIII for 30–60 minutes after the subcutaneous injection to avoid a gap in circulating insulin coverage.
Hyperosmolar Hyperglycaemic State (HHS)
Hyperosmolar Hyperglycaemic State (HHS) is an endocrine emergency typically occurring in older patients with type 2 diabetes. It is characterized by severe hyperglycaemia, extreme hyperosmolality, and profound dehydration in the absence of significant ketoacidosis.
Diagnostic Criteria for HHS
Severe hyperglycaemia: Blood glucose typically > 30.0 mmol/L .
Profound hyperosmolality: Serum osmolality > 320 mOsm/kg (calculated effective osmolality: 2 × [ Na + ] + glucose 2 \times [\text{Na}^+] + \text{glucose} 2 × [ Na + ] + glucose ). Total serum osmolality includes urea: 2 × [ Na + ] + glucose + urea 2 \times [\text{Na}^+] + \text{glucose} + \text{urea} 2 × [ Na + ] + glucose + urea .
Significant hypovolaemia and dehydration.
Absence of significant ketoacidosis: Venous pH > 7.30, serum bicarbonate > 15.0 mmol/L, and capillary blood ketones < 3.0 mmol/L.
Pathophysiological Differences
Unlike DKA, patients with HHS possess sufficient residual endogenous insulin secretion to suppress adipose lipolysis and hepatic ketogenesis, preventing severe metabolic acidosis. However, the insulin level is insufficient to promote peripheral glucose utilisation, leading to escalating hyperglycaemia over days to weeks. The resultant severe osmotic diuresis produces an average fluid deficit of 100–220 mL/kg (8–12 litres in a 70 kg adult) .
Management Principles of HHS
Gradual Fluid Resuscitation: The cornerstone of HHS therapy is fluid replacement using 0.9% sodium chloride . The goal is to slowly expand circulating volume and reduce serum osmolality at a controlled rate of 3–8 mOsm/kg/hour .
Caution on Rapid Osmolality Drops: Precipitous reduction of serum osmolality risks cerebral oedema and central pontine myelinolysis.
Insulin Administration: Unlike DKA, insulin should NOT be started immediately in HHS unless blood ketones are ≥ 1.0 mmol/L or significant acidosis is present. Fluid resuscitation alone lowers glucose through renal clearance and haemodilution. If blood glucose ceases to fall despite adequate rehydration, initiate a low-dose fixed-rate insulin infusion at 0.05 units/kg/hour .
Thromboprophylaxis: Dehydration and extreme hyperviscosity confer an immense risk of arterial and venous thromboembolism. Prophylactic low molecular weight heparin (LMWH) is mandatory for all patients with HHS unless contraindicated.
Comparison: DKA vs Hyperosmolar Hyperglycaemic State
Clinical / Biochemical Parameter Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycaemic State (HHS)
Primary Population Typically Type 1 Diabetes (younger, rapid onset < 24h) Typically Type 2 Diabetes (older, insidious onset days–weeks)
Pathophysiology Absolute insulin deficiency; unchecked lipolysis and ketogenesis Relative insulin deficiency; suppressed lipolysis; massive osmotic diuresis
Capillary Blood Glucose Usually 11.0 – 30.0 mmol/L (or < 11 in euglycaemic DKA) Markedly elevated, typically > 30.0 mmol/L (often > 50 mmol/L)
Blood Ketones (Beta-hydroxybutyrate) ≥ 3.0 mmol/L (or urine ketones ≥ ++) < 3.0 mmol/L (usually normal or mildly elevated)
- Venous pH & Bicarbonate pH < 7.30 ; Bicarbonate < 15.0 mmol/L pH > 7.30 ; Bicarbonate > 15.0 mmol/L
- Serum Osmolality Variable, usually < 320 mOsm/kg > 320 mOsm/kg
- Typical Fluid Deficit ~100 mL/kg (~5–8 litres) ~100–220 mL/kg ( ~8–12 litres )
Primary Initial Therapy 0.9% NaCl + FRIII (0.1 units/kg/h) immediately 0.9% NaCl alone ; add low-dose insulin (0.05 U/kg/h) only if glucose stops falling
Potassium Management Strict titration; add 40 mmol KCl/L if K+ 3.5–5.5 Replace if K+ < 5.5 mmol/L; monitor closely